Promising combo tackles relapsed lymphoma in small trial
NCT ID NCT02433795
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 study tested a combination of two drugs, bendamustine and rituximab, in 27 people with relapsed or progressive marginal zone B-cell lymphoma. The goal was to see how well the treatment shrank or controlled the cancer. Participants had already tried at least one prior therapy. The study is complete, and results may help guide future treatment for this type of lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chonbuk National University Hospital
Jeonju, Jeollabuk-do, 54907, South Korea
-
Chungnam National University
Daejeon, South Korea
-
Gachon University Gil Medical Center
Incheon, South Korea
-
Gyeongsang National University Hospital
Jinju, South Korea
-
Hallym University Medical Center
Anyang-si, South Korea
-
Inje Universit
Seoul, South Korea
-
Korea Cancer Center Hospital
Seoul, South Korea
-
Seoul National University Boramae Hospital
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
The Catholic University of Korea
Seoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bendamustine plus rituximab
What this could lead to
If successful, this combination could offer a treatment option for people with relapsed marginal zone lymphoma, helping to shrink or control the cancer.
What could go wrong
This is a small, phase 2 study with only 27 participants, so results may not apply to everyone. The treatment also has side effects like low blood counts and infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.